// App-Quantinova.ai

: Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study

Researchers

Presenter

  • Walter Giorgio Canonica

Principal Investigators

  • J. Christian Virchow

  • David Singh

  • Maxim Kots

  • Florence Zuccaro

  • Andrea Vele

  • George Georges

  • Stefano Petruzzelli

Medical Centers

  • Humanitas University and Humanitas Research Hospital, Milano, Italy

  • Department of Pneumology/Intensive Care Medicine, University of Rostock, Rostock, Germany.

  • Medicines Evaluation Unit, Manchester, United Kingdom.

  • Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.

Locations

  • Italy

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Salbutamol

  • Tiotropium bromide

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved